Related Experiment Video
Updated: Jul 15, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Triple reuptake inhibitors ("broad spectrum" antidepressants)
Phil Skolnick1, Anthony S Basile
1DOV Pharmaceutical, Inc., USA. pskolnick@dovpharm.com
Abstract:
The majority of antidepressants in current use inhibit the uptake of serotonin and/or norepinephrine. Drugs inhibiting the uptake of serotonin, norepinephrine and dopamine (triple reuptake inhibitors) may offer therapeutic advantages compared to single and/or dual reuptake inhibitors. This review provides a rationale for developing this class of compound and describes the results of preclinical and clinical studies with a family of triple reuptake inhibitors.
Related Concept Videos
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Drugs Affecting Neurotransmitter Release or Uptake
G-protein Coupled Receptors
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
